Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (NASDAQ:BIIB) vs. Vitro Diagnostics (OTCMKTS:VODG) Critical Contrast

01:15am, Wednesday, 22'nd Jul 2026

Vitro Diagnostics (OTCMKTS:VODG - Get Free Report) and Biogen (NASDAQ: BIIB - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based

Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System

04:27am, Monday, 20'th Jul 2026

California Public Employees Retirement System raised its position in Biogen Inc. (NASDAQ: BIIB) by 3.1% in the first quarter, according to the company in its most recent filing with the Securities and

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

07:47am, Thursday, 16'th Jul 2026

Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure,

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

11:55am, Wednesday, 15'th Jul 2026

BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.

Biogen Appoints Michael J. Parini as Chief Legal Officer

08:15am, Wednesday, 15'th Jul 2026

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

05:29pm, Tuesday, 14'th Jul 2026

Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript

Biogen Backs Alzheimer's Tau Drug for Phase 3 Despite Trial Miss

03:02pm, Tuesday, 14'th Jul 2026

Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary

Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi

01:16pm, Tuesday, 14'th Jul 2026

BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.

Stocks Steady as Upbeat Inflation Battles IBM Earnings

12:03pm, Tuesday, 14'th Jul 2026

Stocks are cautiously higher midday, as cooler inflation helps investors forget about higher oil prices

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat

12:00pm, Tuesday, 14'th Jul 2026

LEQEMBIÂ Real-World LEADER Study Presented at AAICÂ 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable a

Why Is Biogen Stock Falling Tuesday?

11:49am, Tuesday, 14'th Jul 2026

Biogen Inc. (NASDAQ:BIIB) on Tuesday said it will advance investigational Alzheimer's therapy diranersen into Phase 3 testing after new Phase 2 data showed the tau-targeting treatment slowed clinical

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by